Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction.
ablation
clinical decision-making
comorbidities
elderly
hepatocellular carcinoma
pattern of progression
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jun 2023
21 Jun 2023
Historique:
received:
10
05
2023
revised:
03
06
2023
accepted:
14
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process.
METHODS
METHODS
We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy.
RESULTS
RESULTS
A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0,
CONCLUSIONS
CONCLUSIONS
These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Identifiants
pubmed: 37444380
pii: cancers15133269
doi: 10.3390/cancers15133269
pmc: PMC10339895
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World J Surg Oncol. 2017 Jul 5;15(1):122
pubmed: 28679433
Clin Mol Hepatol. 2016 Dec;22(4):477-486
pubmed: 28081587
J Vasc Interv Radiol. 2023 Jan;34(1):1-3
pubmed: 36244632
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Ann Oncol. 2021 Jun;32(6):801-805
pubmed: 33716105
PLoS One. 2020 Nov 10;15(11):e0242113
pubmed: 33170894
J Gastroenterol. 2003;38(10):977-81
pubmed: 14614605
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
Hepatology. 2005 Jun;41(6):1407-32
pubmed: 15880505
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Cancer. 2003 Mar 1;97(5):1253-62
pubmed: 12599233
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
PLoS One. 2022 Feb 23;17(2):e0264075
pubmed: 35196341
Eur Radiol. 2021 May;31(5):3053-3064
pubmed: 33175203
Eur J Radiol. 2021 May;138:109623
pubmed: 33711573
Eur Radiol. 2022 Jun;32(6):4168-4176
pubmed: 35133486
J Vasc Interv Radiol. 2017 Oct;28(10):1432-1437.e3
pubmed: 28757285
Jpn J Clin Oncol. 2007 Sep;37(9):658-72
pubmed: 17766723
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
J Hepatol. 2019 May;70(5):866-873
pubmed: 30615906
J Clin Oncol. 2019 Jan 1;37(1):22-32
pubmed: 30388045
J Gastroenterol Hepatol. 2012 Jun;27(6):1044-50
pubmed: 22433056
Eur J Radiol. 2011 Aug;79(2):196-200
pubmed: 20303686
PLoS One. 2013 Jul 29;8(7):e70016
pubmed: 23922893
Hepatology. 2009 Nov;50(5):1475-83
pubmed: 19731239
Liver Int. 2022 Apr;42(4):905-917
pubmed: 34894060
Am J Gastroenterol. 2009 Nov;104(11):2747-53
pubmed: 19603009
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
J Gastrointest Surg. 2022 Mar;26(3):615-622
pubmed: 34618325
Hepatology. 2023 May 22;:
pubmed: 37199193
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Cancers (Basel). 2021 May 30;13(11):
pubmed: 34070800
Eur Radiol. 2020 Jan;30(1):186-194
pubmed: 31372783
Eur J Radiol. 2006 Sep;59(3):432-41
pubmed: 16690240
Hepatology. 2004 Dec;40(6):1352-60
pubmed: 15565564
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Am J Cancer Res. 2021 Oct 15;11(10):5126-5140
pubmed: 34765316
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Lancet. 2022 Oct 15;400(10360):1345-1362
pubmed: 36084663
Cancers (Basel). 2020 Sep 05;12(9):
pubmed: 32899584